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2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma
receiving maintenance therapy with interferon a2b do not correlate with
clinical response
BC Millar and JBG Bell
Section ofAcademic Haematology, The McElwain Laboratories, Institute ofCancer Research, Sutton, Surrey, UK.
Summary In clinical trials with interferon a2b (IFN-a2b) as maintenance therapy for multiple myeloma, the
therapeutic benefit is inconclusive. Although the mechanism(s) by which IFN-a2b prolongs remission in some
patients is unknown, 2',5'-oligoadenylate synthetase (2,5-A synthetase) has been used as an objective indicator
that IFN-a2b is active in vivo. The enzyme was assayed in cytosol preparations of peripheral blood
mononuclear cells (MNCs) from 111 patients who were receiving IFN-a2b and 54 patients who were not,
using an assay which measures the conversion of [a-32P]ATP to triphospho(adenylyl 2',5')adenosine. 2,5-A
synthetase activity was compared with response to intensive therapy and with duration of maintenance
therapy. Seventy-three per cent of patients had measurable amounts of 2,5-A synthetase during the first 6
months of maintenance therapy. This percentage decreased with longer follow-up but not significantly. There
was no difference between the magnitude of enzyme induction amongst patients who were in complete
remission, partial response or who had no change in disease status following intensive therapy. Peripheral
blood T cells were a major source of 2,5-A synthetase activity in patients receiving the cytokine. However,
both T and B cells produced the enzyme following exposure to IFN-a in vitro. The data show that the level of
2,5-A synthetase in patients with multiple myeloma is not indicative of clinical response to IFN-a2b.
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The interferons are a heterogeneous group of proteins that
have pleiotropic effects as well as their known anti-viral
activity. Interferon a (IFN-m) is the most widely used and is
available commercially, from recombinant technology, as
IFN-a2a (Roferon), IFN-a2b (Intron-A) and IFN-a2c.
The therapeutic benefit of IFN-a as maintenance therapy
for patients with multiple myeloma remains inconclusive. In
the first randomised trial, the initial suggestion by Mandelli
et al. (1990) that IFN-a might produce a survival benefit,
following chemotherapy to objective response, was not
confirmed with longer follow-up of the same patients
(Avvisati et al., 1993). Two other randomised trials produced
similar results, although all three studies confirmed a
significant prolongation of remission compared with patients
who received no further treatment (Ludwig et al., 1991;
Westin, 1993). In three other randomised studies,
maintenance therapy with IFN-a produced neither prolonga-
tion of remission nor a survival benefit (Peest et al., 1990;
Bird et al., 1993; Salmon et al., 1994). Results from a non-
randomised French study suggest that IFN-a can prolong
remission after chemotherapy with autologous bone marrow
rescue (ABMR)(Attal et al., 1992). Also in an ongoing study
at the Royal Marsden Hospital patients who were ran-
domised to receive IFN-a2b after high-dose melphalan
(HDM) and ABMR show a significantly longer duration of
remission and survival compared with those who have had
no further treatment (Cunningham et al., 1993). However, in
both of these studies the benefit of IFN-a was confined to
patients who entered complete remission after ABMR. These
data suggest that the efficacy of IFN-x in stabilising residual
disease is greatest when there has been a substantial reduc-
tion of the tumour burden.
The mechanism(s) by which IFN-a stabilises remission in
some patients is unknown. It has yet to be determined wheth-
er the cytokine acts directly by inhibiting the proliferation of
the malignant clone or indirectly by immune modulation.
Furthermore, it is not known whether IFN-a remains
biologically active when given long term to patients, or
whether it is necessary to give IFN-a throughout the dura-
tion of remission until relapse. We have shown previously
that neutralising antibody production against IFN-a in
patients who receive the cytokine as maintenance therapy is
transitory and unlikely to account for relapse (Bell et al.,
1994). However, recent evidence suggests that some cancer
patients who receive IFN-a produce an inhibitor (IIF) which
blocks the effects of the recombinant cytokine in vitro and is
not antibody (Medenica et al., 1994). This raises the pos-
sibility that IFN-a may be ineffective in some patients and
may be wasteful of an expensive resource.
Treatment of cells with IFN-a results in the induction of
2'-5' oligoadenylate synthetase (2,5-A synthetase) which
catalyses the polymerisation of ATP to triphospho(adenylyl
2',5')adenosine (Kerr and Brown, 1978; Baglioni, 1979). This
oligomer is required for the activity and stability of
ribonuclease L which degrades mRNA and rRNA and conse-
quently inhibits protein synthesis (Nilsen et al., 1981). An
increase in the activity of 2,5-A synthetase is a very sensitive
indication that cells have been in contact with IFN-a. In
patients, induction reaches a maximum approximately 8 h
after the administration of the cytokine and elevated levels
persist for at least 24h following cessation of treatment.
However, the magnitude of enzyme induction in individual
patients shows considerable variation (Merritt et al., 1985).
In patients with chronic lymphocytic leukaemia (CLL) receiv-
ing IFN-a, the degree of induction of mRNA for 2,5-A
synthetase was statistically different between good, inter-
mediate and poor responders, suggesting that measurement
of the enzyme might be indicative of clinical response (de
Mel et al., 1990). Furthermore, although the exact role of
2,5-A synthetase in the action of IFN-a is unclear, in patients
with hairy cell leukaemia and B-cell CLL its induction has
been linked directly to the anti-proliferative effect of pento-
statin (Ho et al., 1992). In our patients induction and high-
dose therapy before maintenance with IFN-a2b, results in a
substantial reduction in the tumour burden. Thus, conditions
in vivo may not be comparable with those in patients with
other haematological malignancies who have had no other
treatment. Furthermore, since the stem cell in multiple
myeloma is unknown it is not possible to determine whether
IFN-a2b has a direct effect on the malignant clone, partic-
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ularly when the number of putative precursors cells are likely
to have been substantially reduced. However, because induc-
tion of 2,5-A synthetase in vitro in phytohaemagglutinin-
treated peripheral blood MNC from normal donors and
patients with hairy cell leukaemia correlates with the anti-
proliferative effect of IFN-o2b (Billard et al., 1987), we feel
justified in using MNC from our patients as a starting point
to investigate the possible contribution of this enzyme.
In this report, we measured 2,5-A synthetase activity in
peripheral blood mononuclear cells from patients receiving
maintenance therapy with IFN-o2b after HDM followed by
ABMR or autologous peripheral blood stem cell rescue
(PBSCR). The aims of the experiments were to determine
whether there was a significant difference in the magnitude of
enzyme induction between patients who have a complete
remission, a partial response or no further response to inten-
sive therapy. We also measured the levels of 2,5-A synthetase
in patients at different times from the start of maintenance
therapy to determine whether there was a decline in activity
following prolonged exposure to IFN-a2b. In patients from
whom sequential blood samples were available we deter-
mined whether loss of enzyme activity is indicative of relapse.
Materials and methods
Clinical samples
Patients and donors gave informed consent for blood sam-
ples to be taken, following approval from the local ethics
committee at the Royal Marsden Hospital. Peripheral blood
samples were collected by venepuncture from multiple
myeloma patients and normal donors at outpatient clinics.
Wherever possible, patients were requested to undergo
venepuncture at 3-monthly intervals during treatment with
IFN-uo2b. Amongst patients who were receiving IFN-a2b,
blood samples were taken within 24 h ofdrug administration.
Patients who presented at the Royal Marsden Hospital
received one of two conditioning regimens, either CY-VAMP
[i.v. infusion of vincristine, 0.4 mg and doxorubicin, 9 mg
m-2 over 24 h for 4 days with bolus methylprednisolone
(1.5 g i.v. or orally daily for 5 days) plus cyclophosphamide
(500 mg i.v. bolus on days 1, 8 and 15)] or VERCY-VAMP
[vincristine, doxorubicin, methylprednisolone and cyclophos-
phamide (doses as before) plus verapamil (10 mg i.v. over
24 h for 5 days)] followed by HDM either 200 mgm2 with
ABMR or PBSCR or 140 mg m-2 alone. Patients were given
IFN-o2b (Intron-A, Schering-Plough) at 3 x 106U m-2 sub-
cutaneously three times weekly when the leucocyte count was
greater than 3 x 101-' and platelets were greater than
100 x 109 1-1.
Clinical status
A complete remission (CR) was defined as the absence of
measureable paraprotein and bone marrow infiltration by
myeloma cells of< 5%. A partial response (PR) was defined
as a paraprotein reduced by 50% and improvement in
clinical features sustained for longer than 1 month.
Preparation ofcell extracts
Mononuclear cells (MNCs) were isolated within 2 h of
venepuncture following separation over Ficoll-Hypaque
(Boyum, 1968). They were resuspended in RPMI-1640 con-
taining 10% fetal calf serum (FCS) and counted. Aliquots of
cell suspensions containing approximately 6 x 106 MNCs
were pelleted at 12 000 g for 30 s. The medium was aspirated
from the cells and residual red cell contamination was
removed by incubation with Ortho lysis buffer (Ortho Diag-
nostics Systems, UK) for 10 min at room temperature. The
cells were pelleted as before and resuspended in 50-100 gil of
lysis buffer [20 mM Hepes, pH 6.9, 5 mM potassium chloride,
5 mM Mg(OAc)2, 1 mM dithiothreitol (DTT) and 0.5%
Nonidet P140]. MNCs were subjected to two cycles of freez-
ing and thawing at - 80°C followed by ultrasonication for
2 min. Cell debris was removed by centrifugation at 12 000 g
for 2 min and the supernatants were stored at - 80°C until
use. This procedure did not result in loss of 2,5-A synthetase
activity compared with that found in samples assayed
immediately after preparation of cell extracts.
Aliquots of 5 gil of each cell extract were used to determine
the protein concentration using a UV spectrophotometer
(Shimadzu UV 1201) calibrated at 260 nm.
Assayfor 2',5'-oligoadenylate synthetase
The method used to measure 2,5-A synthetase was similar to
that developed by Minks et al. (1979). The assay buffer
consisted of 0.12 M Mg (OAc)2, 20 mM Hepes/potassium hyd-
roxide buffer, pH 7.4, 5 mM ATP, 1 mM DTT and 10 gig ml-'
polyI:polyC. For assay purposes, 4 gIl of a-labelled [32P]ATP
(3000 Ci M-', Amersham International, cat. no. PB 10200)
was added to 1 ml of assay buffer at the start of each
experiment. An aliquot of 1 gil of the complete buffer was
used to determine the total radioactivity in the reaction
mixture. This was approximately 100 000 c.p.m. gl-'.
The assay contained 5 gIl of cell extract and 20 gl of assay
buffer. Duplicate samples of each cell extract were incubated
with gentle agitation at 37°C for 19 h. At this time,
oligonucleotides were digested with 2 glI of T-2 ribonuclease
(0.1 U; from Aspergillus oryzae, Sigma, UK) or snake venom
(0.001 U; Crotalus atrox, Sigma, UK) for 1 h at 37°C. All
extracts were then treated with bacterial alkaline phosphatase
(0.1 U; Escherichia coli, Sigma Ltd, UK) for 90 min at 37°C.
The cell extracts were then heated at 95°C for 2 min and
centrifuged at 12 000 g for 2 min. Aliquots of 2 glI were spot-
ted onto thin-layer chromatography plates (0.1 mm cellulose
MN polyethyleneimine impregnated; Polygram, Macherey-
Nagel, Germany) and run with 1 M lithium chloride solvent
for 2 h. The chromatograms were autoradiographed over-
night (Biomax FilmX-OMAT, Kodak, USA) and the prod-
ucts located on the chromatograms from the developed
autoradiographs. Products were cut from the chromatograms
and counted in a P-counter in 10 ml of scintillation fluid
(Ultima Gold; Packard, USA). Preliminary experiments were
done to confirm the stability of the enzyme following freezing
and thawing and the nature of the products which were
mostly dimers (Minks et al., 1979; Merritt et al., 1985). In
addition, MNCs were assayed from a normal volunteer dur-
ing two separate infectious episodes immediately and after
incubation for 24 and 48 h to determine the half-life of 2,5-A
synthetase, which was shown to be 24 h (data not shown).
Purification ofB and T-cells
The number of T and B cells in MNC were estimated using
dual-labelled fluorescence-activated cell analysis (FACS) with
monoclonal antibodies conjugated to fluorescene isothio-
cyanate (FITC) or phycoerythrin (PE) and directed against
CD19 and CD3 (Beckton Dickinson, UK,) and CD4, CD8,
CD14 and CD45 (Sigma, UK) using an Ortho Cytoron and
the software package provided by the manufacturer (Ortho
Diagnostics Systems, UK). B and T cells were isolated using
antibody coated magnetic beads conjugated to CD19 (B cell)
or CD2 (T cell) with a bead to cell ratio of 3:1 and detached
from the same by methods described by the manufacturer
(Dynal, UK). Viable cells were counted in a haemocytometer
using trypan blue exclusion. Isolated B and T cells were
incubated at 2 x 106 ml-' in RPMI-1640 supplemented with
10% FCS, 100 gigml' penicillin and 100 Umlh' strep-
tomycin and containing 100 U ml' IFN-a2b (Intron A) or
the same volume of phosphate-buffered saline (PBS). After
incubation for 20h, cells were harvested and processed as
above. In experiments in which T cells were isolated from the
peripheral blood ofpatients who were receiving IFN-a2b, cell
extracts were prepared immediately after separation from the
MNCs, without detachment from magnetic beads.
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WAStatistical analysis
Statistical analysis was done using non-parametric tests in a
software package.
Results
Two hundred samples from 111 patients who were receiving
IFN-a2b and 87 samples from 54 patients who had not
received the cytokine were available for testing.
The data in Table I show that 2,5-A synthetase activity
was detected in 36/54 (67%) of patients with multiple
myeloma who were not receiving maintenance therapy with
IFN-a2b. These included nine patients who had had no
previous chemotherapy. The remainder were patients who
had had induction therapy alone (11 patients) or induction
therapy followed by HDM/ABMR or PBSCR (16 patients).
Since enzyme activity in these patients was likely to be due to
infection which was documented in some patients after inten-
sive therapy, the data suggest that their response to
endogenous IFN was not impaired by intensive therapy.
Three of 12 normal donors who were known to have infec-
tion at the time of testing also had measurable enzyme
activity.
Amongst patients who were having maintenance therapy
with IFN-a2b 73% had measurable 2,5-A synthetase activity
during the first 6 months of treatment. With longer follow-up
this percentage decreased but not significantly. There was
considerable variation in the absolute amount of enzyme in
individual patients, which showed no correlation with the
clinical response to intensive therapy. Although there was a
tendency for enzyme activity to decline with longer periods of
maintenance therapy this was not statistically significant
(Table I).
During the time period over which samples were accrued,
peripheral blood from 8/22 patients who remain in CR after
HDM/ABMR and who are included in the Royal Marsden
Hospital Trial with IFN-a2b as maintenance therapy (Cunn-
ingham et al., 1993) was available for testing. Five of these
eight patients had measurable levels of 2,5-A synthetase
activity 34-72 months after commencing therapy with IFN-
a2b (Table II).
Examination of sequential blood samples from individual
patients shows that in three patients loss of 2,5-A synthetase
activity was associated with relapse (Table III, patients 9, 12
and 14). Two of these patients had had PBSCR (patients
nine and 14) and one had had ABMR (patient 12) after
HDM. In one of these patients (patient 14) maintenance
therapy with IFN-a2b was continued during progressive
disease and the enzyme activity increased subsequently.
Throughout the duration ofmaintenance therapy neutralising
antibodies to IFN-a2b were not detected. In two patients
2-5Asynthetass in myoloma padents
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who failed to show induction of the enzyme, there was no
way of identifying whether relapse was imminent (Table III,
patients 11 and 13). Both of these patients had had HDM
with PBSCR.
When enzyme activity was compared in purified T cells
and MNCs from three patients who were receiving IFN-a2b
there was substantially more enzyme activity in the T-cell
fraction (Table IV). However, both B cells and T cells pro-
duced substantial amounts of 2,5-A synthetase following
overnight exposure to recombinant IFN-a2b in vitro (Table
V).
Discussion
At the Royal Marsden Hospital the majority of newly diag-
nosed patients with multiple myeloma will receive maint-
enance therapy with IFN-a2b after intensive therapy with
HDM/PBSCR. This is based on the encouraging results from
an ongoing study in which more than 50% of patients who
entered CR after HDM/ABMR followed by maintenance
therapy with the cytokine remained in remission for more
than 4 years and have had a significant survival advantage
(Cunningham et al., 1993). The mechanism(s) which is
involved in mediating these effects are unclear.
In solid tumours, such as melanoma and renal cell car-
cinoma the anti-tumour effect of IFN-o may be mediated by
the immune response, including the activation of NK cells
and the enhanced expression of cell-surface markers (e.g.
MCH 1 and II: Dorr, 1993). However, there is no evidence
that natural killer (NK) (Galvani et al., 1989; Klingemann et
al., 1991), lymphokine-activated killer (LAK) or T-cell
cytotoxicity (Griffiths and Cawley, 1988) is involved in the
anti-tumour response in haematological malignancies.
In an interleukin 6 (IL-6) dependent myeloma cell line
IFN-o inhibits proliferation in vitro by depriving cells of
Table II 2'-5'Oligoadenylate synthetase activity in MNCs from
patients in CR receiving IFN-ao2b therapy after HDM/ABMR
Time ofIFN-c2b Enzyme activity
Patient Treatment (months) (pmol/lfg-
I protein h-)
1 22 4.4
35 3.02
2 37 -ve
43 -ve
3 26 11.1
4 58 5.08
5 24 3.13
6 75 -ve
7 52 48.8
8 26 -ve
Table I Correlation of2'-5'oligoadenylate synthetase activity in MNCs from multiple myeloma patients before and
during maintenance therapy with IFN-a2b with clinical status
Patients with Clinical
Total detectable Enzyme activity in status Enzyme activity in
Time of number of enzyme activity pmolpg-'proteinh' (no. of pmolj.g-' proteinh'
treatment patients No. (%) Median (range) patients) Median (range)
Pretreatment 54 36 (67) 11.0 (2.02-148)
0-6 months 52 38 (73) 13.7 (2-166) CR (12) 11.20 (2.6-100)
PR (14) 15.25 (2.0-166)
NC/PD (12) 13.10 (3.2-58.3)
7-12 months 22 11 (50) 8.78 (2.27-80.6) CR (5) 8.78 (2.27-28)
PR (3) 36.60 (3.4-80.6)
NC/PD (3) 7.10 (4.3-33.9)
> 12 months 37 24 (65) 4.89 (2.1-48.8) CR (9) 5.08 (3.02-48.8)
PR (6) 7.78 (2.8-16.7)
NC/PD (9) 4.68 (2.1-27.8)
Normal 12 3 (25) 4.5 (3.6-7.2)
CR, complete remission; PR, partial response; NC, no change or plateau phase; PD, progressive disease.2-5Asynthetase in mysloma patients 00 BC Millar and JBG Bell etal
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TableHI 2'5'Oligoadenylate synthetaseactivity inMNCtakensequentially from
multiple myeloma patients during maintenance therapy with IFN-a2b
Clinical Time ofinterferon-x2b Enzyme activity
Patient status treatment (months) (pmol tg'- protein h-')
CR 7 2.27
9 CR 12 18.5
CR 18 -ve
PD 20 -ve
10
11
12
13
14
CR
CR
CR
CR
CR
CR
CR
PR
PR
PR
PR
PR
PD
NC
NC
NC
NC
PR
CR
CR
CR
PD
NC
NC
5
8
9
13
5
8
Died at 14
6
9
12
13
15
PD at 20
2
7
12
Pretreatment
1
6
9
10
11
12
17.0
7.95
10.0
28.0
11.0
-ve
-ve
20.7
37.8
35.4
16.7
1.6
-ve
-ve
-ve
-ve
-ve
4.2
16.0
1.2
0.34
16.3
33.9
6.2
CR, complete remission; PR, partial response; NC, no change orplateauphase;
PD, progressive disease.
Table IV Comparison of 2',-5'-oligoadenylate synthetase activity in
MNCs and T cells in multiple myeloma patients receiving IFN-a2b
therapy
Enzyme activity
(pmol;Lg-
I proteinh-')
Patient MNCs T cells
15 3.25 55.8
16 11.1 126.3
17 3.8 25.0
Table V 2',-5'-Oligoadenylate synthetase activity in isolated B and T
cells from multiple myeloma patients not receiving IFN-m2b following
exposure to 100 U ml-' IFN-a2b in vitro
Enzyme activity
Patient Cell type (pmoljg-' protein h)
18 B cells 58.9
19 B cells 156.8
20 T cells 7.3
21 Tcells 14.7
22 T cells 68.1
functional IL-6 receptors, thereby interrupting an essential
autocrine loop (Schwabe et al., 1994). Other workers have
suggested that a similar mechanism may be involved in the
anti-proliferative effect of IFN-x in patients with hairy cell
leukaemia and B-cell leukaemia and that it may be mediated
by 2,5-A synthetase (Heslop et al., 1991).
In this study, there was no correlation between disease
status after intensive therapy for multiple myeloma and our
ability to measure 2,5-A synthetase. The finding that the
enzyme was not measurable in a significant number of
patients suggests that resistance to induction of this protein
by IFN-x2b can develop early during treatment. In CML,
resistance to IFN-x has been ascribed to post-translational
modification of the enzyme since there was no consistent
defect in the expression of mRNA transcripts for 2,5-A
synthetase in patients who were resistant or sensitive to the
cytokine (Talpaz et al., 1992).
Among patients who had measurable levels of 2,5-A syn-
thetase there was considerable inter-patient variation, in
agreement with earlier studies (Merritt et al., 1985) but there
was no correlation between the magnitude of the enzyme
activity and response to intensive therapy. Some of this
variability is likely to be due to the distribution of cell types
within individual samples and the contribution that each cell
type makes to the total enzyme activity in the MNC fraction.
In our patients, T lymphocytes were a major source of the
enzyme, however it is likely that both B and T cells cont-
ribute to enzyme activity in vivo since both cell types showed
enzyme induction after exposure in vitro to IFN-a2b.
The loss of enzyme activity at progressive disease in three
patients suggests that the mechanism(s) which maintains mul-
tiple myeloma in a non-proliferative state can be evaded in
the absence of2,5-A synthetase. However, it is not proof that
2,5-A synthetase is a prerequisite for maintaining tumour
homeostasis. Once tumour cell proliferation had been
initiated in vivo, subsequent recovery of the enzyme as in the
patient who continued to receive IFN-m2b during relapse,
was not accompanied by inhibition of tumour cell prolifera-
tion. Furthermore, 2,5-A synthetase was not detected in three
patients who remain in long-term remission but was found in
nine patients at presentation. In a study of seven patients
receiving IFN-x for hairy cell leukaemia, one of two non-
responders had similar levels of 2,5-A synthetase to those
found in patients who responded to the cytokine (Billard et
al., 1988). Collectively this report and our data suggest that
other mechanisms which do not involve 2,5-A synthetase
may be involved in the anti-tumour effect of IFN-o2b.
In the study of IFN-x as maintenance therapy for multiple
myeloma by the South West Oncology Group, although2-5Asynthetass in myelomapatients
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IFN-m2b alone was ineffective, addition of glucocorticoids
improved the clinical outcome (Salmon et al., 1994). The
authors proposed that long-term glucocorticoid administra-
tion in multiple myeloma during both remission induction
and maintenance may result in the best survival overall. At
the Royal Marsden Hospital all patients who have had
HDM/ABMR received methylprednisolone 1 gm2 for 5
days immediately after HDM and before the start of
maintenance therapy (Cunningham et al., 1993). Whether the
continued CR of three out of eight of these patients, despite
the absence of 2,5-A synthetase, was determined by the
glucocorticoid treatment per se or augmented an anti-
proliferative effect which was independent of the enzyme
cannot be resolved. In the current treatment protocol
patients who have had HDM/PBSCR have not had
methylprednisolone after HDM. The finding that two
patients who have relapsed from CR after HDM/PBSCR at
20 months (patient 9) and 10 months (patient 14) following a
decline in 2,5-A synthetase while receiving IFN-a2b may be
relevant to this proposition. Whether administration of
methylprednisolone after HDM/ABMR has been a determin-
ing factor in the prolongation of remission and/or survival
benefit in patients who achieved CR and were given IFN-o2b
subsequently may become apparent as patients are followed
who have PBSCR.
In conclusion, the findings that some patients did not
produce 2,5-A synthetase while receiving the cytokine sug-
gests either that IFN--2b was inactive in these patients or
that induction of this enzyme is irrelevant to the suppression
of the malignant clone by IFN-x2b. In other haematological
malignancies the correlation between 2,5-A synthetase levels
and clinical response occurs in patients who receive IFN-a2b
as sole treatment (de Mel et al., 1990; Ho et al., 1992)
suggesting that enzyme levels reflect an antiproliferative
effect. However, this may not be analogous to the conditions
in our patients who have had intensive therapy before receiv-
ing the cytokine and in whom IFN-a2b is given to prolong
the response to HDM rather than illicit tumour cell kill.
Although the mechanism(s) involved in tumour growth
inhibition remains elusive the data suggest that there is a
critical balance between the tumour mass and its proliferative
state which must be achieved to enable IFN-a2b to maintain
homeostasis. Further studies may determine whether restora-
tion of normal haemopoiesis, which may effect tumour
homeostasis, occurs independently of the induction of 2,5-A
synthetase in multiple myeloma patients receiving IFN-a2b as
maintenance therapy. Such studies may result in a more
effective and economical use of an expensive resource.
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